Darifenacin
A selective muscarinic M3 receptor antagonist used to treat overactive bladder by reducing involuntary bladder contractions that cause urgency, frequency, and urge incontinence. Its relative M3 selectivity may reduce some anticholinergic side effects compared to less selective agents.
分子量
426.5000 g/mol
LogP
4.60
TPSA
55.60 Ų
リピンスキーの五則
適合
治療領域
作用機序
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
2D構造
Cite this structure
Embed this structure
SMILES
NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1
InChI
InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1
Molecular Formula
C28H30N2O2
HBD / HBA
1 / 3
回転可能結合数
7
重原子数
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
A selective muscarinic M3 receptor antagonist used to treat overactive bladder by reducing involuntary bladder contractions that cause urgency, frequency, and urge incontinence. Its relative M3 selectivity may reduce some anticholinergic side effects compared to less selective agents.
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Yes, Darifenacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1346. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 444031. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="darifenacin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/darifenacin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/darifenacin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/darifenacin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="darifenacin"></drugfyi-drug>